Social Media Ideas for Agerion

Amylyx’s bet on a GLP-1 blocker pays off

A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery...

Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win

Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes b...

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug

Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca...

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

<![CDATA[Pharmaceutical Executive Daily: Jazz Acquires Actio Bioscience]]>

Amylyx Plans FDA Filing After GLP-1 Drug Hits Trial Goals in Rare Metabolic Condition

Amylyx Pharmaceuticals’ avexitide led to statistically significant and clinically meaningful reductions in hypoglycemic events in patients with post-bariatric hypoglycemia (PBH). T...

Supernus, Individor merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Pa...

Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences

Based in Cambridge, MA, Merida develops biologic drugs that are engineered to selectively degrade pathogenic autoantibodies linked to a number of immune-mediated conditions. Merida...

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

Novo Nordisk: The Oral Wegovy Promise

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

<![CDATA[Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics for alvelestat ]]>

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

Novo's False Ad Suit Against Eli Lilly Ramps Up GLP-1 Rivalry

Pharmaceutical giant Novo Nordisk Inc. slapped rival Eli Lilly & Co. with a false advertising suit in New Jersey federal court Tuesday, calling a marketing campaign for the riv...

<![CDATA[BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment ]]>

Roche commits to lean-mass preservation with Hanmi obesity deal

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

<![CDATA[Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration]]>

<![CDATA[FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia ]]>

Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads

Novo Nordisk Inc. asked a New Jersey federal court Friday to block rival Eli Lilly & Co. from running ads allegedly comparing their respective GLP-1 drugs using "outdated" clin...

Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday

Actimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 millio...

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don't Qualify

WEDNESDAY, Aug. 26, 2026 — In January, Jeff La Marca got a prescription for the popular weight loss drug Zepbound. But he couldn’t afford the $750 monthly price tag. “I thought, ‘T...